ViSE
-
VISE symposium explores interoperative fluorescence to light up tumors
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreDec. 18, 2017
-
Tech transfer course gives grad students real-world journey
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreDec. 9, 2017
-
NIH-funded collaboration to develop steerable robotic needles for lung biopsies
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreNov. 8, 2017
-
VISE team wins $1.4 million NIH grant to reboot robotic surgery system
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreOct. 17, 2017
-
BME study shows software helps surgeons find liver tumors, avoid blood vessels
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreJul. 17, 2017
-
Five students earn awards at SPIE Medical Imaging Conference
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreMar. 2, 2017
-
Fresh from company launch and I-Corps, Webster passes lessons along
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreDec. 15, 2016
-
New VISE grant gives clinical boost to surgical device development
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreJun. 20, 2016
-
Entrepreneurs pack panel at VISE symposium, alum Tyler-Kabara wows with keynote
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreDec. 21, 2015
-
Surgery and engineering initiative becomes institute
Using fluorescently labeled antibodies as a contrast agent can give cancer surgeons highly specific real-time detection of tumors that may accelerate diagnosis, preserve more healthy tissue, and improve patient outcomes. Dr. Eben Rosenthal, keynote speaker at the VISE symposium, discusses using near-infrared fluorescence to improve detection of cancer margins. (Joe… Read MoreSep. 10, 2015